Trials / Completed
CompletedNCT03370770
Afatinib Osimertinib Sequencing NIS
GioTag: Real-world Data Study on Sequential Therapy With Gi(l)Otrif®/ Afatinib as First-line Treatment Followed by Osimertinib in Patients With EGFR Mutation Positive Advanced Non-small Cell Lung Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 204 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-interventional, multi-country, multi-centre cohort study based on existing data from medical records of patients with EGFR mutation-positive advanced NSCLC treated with afatinib (Gi(l)otrif®) as the first-line treatment followed by osimertinib in case the T790M resistance mutation was developed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Afatinib | GILOTRIF, GIOTRIF, XOVOLTIB |
| DRUG | Osimertinib | on T790M resistance mutation was developed |
Timeline
- Start date
- 2017-12-28
- Primary completion
- 2019-11-28
- Completion
- 2019-11-28
- First posted
- 2017-12-12
- Last updated
- 2020-12-24
- Results posted
- 2020-12-24
Locations
1 site across 1 country: Austria
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03370770. Inclusion in this directory is not an endorsement.